Tacrolimus and Proteinuria: Clinical Implications and Management

Mechanisms and Effects

Tacrolimus is a calcineurin inhibitor with potent immunosuppressive properties, up to 100 times more potent than cyclosporine in vitro, acting by inhibiting T-lymphocyte activation 1
Tacrolimus can affect glomerular permeability, including influence on permselectivity and charge selectivity, contributing to its effects on proteinuria 2

The Kidney International guideline recommends tacrolimus as an alternative first-line therapy for patients with focal segmental glomerulosclerosis (FSGS) and contraindications to high-dose corticosteroids 3, 4
For lupus nephritis, the American Journal of Kidney Diseases suggests tacrolimus has efficacy in achieving earlier remission compared to standard therapy when used in multitarget therapy with mycophenolic acid analogs (MPAA) 5
Tacrolimus can be considered for maintenance therapy in lupus nephritis if mycophenolic acid analogs and azathioprine cannot be used 7, 8
Target trough levels of 5-10 ng/ml (6-12 nmol/l) are generally recommended when using tacrolimus to reduce proteinuria 3

Regular monitoring of tacrolimus blood levels is essential to prevent toxicity, with consideration of dosage reduction or temporary interruption if serum creatinine increases by 30% above baseline 2, 6
Monitoring should include serum creatinine, with a reduction in dose if it increases by 30% above baseline 2